Primary Hyperparathyroidism and Other Causes of Hypercalcemia

  • Charles Y. C. Pak
Part of the Topics in Bone and Mineral Disorders book series (TOHE)


Primary hyperparathyroidism continues to be one of the leading causes of Ca urolithiasis.1–5 Although the exact pathogenetic mechanism for the stone formation in primary hyperparathyroidism has not been clarified, effective control of urolithiasis can usually be achieved by the surgical removal of abnormal parathyroid tissue. 6,7 This condition is not too difficult to diagnose when it is fully manifested. However, primary hyperparathyroidism may escape detection in its subtle presentation and may be confused with other forms of Ca urolithiasis. 8,9 This difficulty has resulted in the recommendation of parathyroid exploration, albeit infrequently, in renal 10 and absorptive 11 hypercalciurias. The following cases illustrate examples of such useless surgery.


Bone Resorption Primary Hyperparathyroidism Calcium Oxalate Serum iPTH Osteitis Fibrosa 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cope, O. 1966. The story of hyperparathyroidism at the Massachusetts General Hospital. N. Engl. J. Med. 274: 1174–1182.PubMedCrossRefGoogle Scholar
  2. 2.
    Bone, H. G., HI, Snyder, W. H., III, and Pak, C. Y. C. 1977. Diagnosis of hyperparathyroidism. Annu. Rev. Med. 28: 111–117.PubMedCrossRefGoogle Scholar
  3. 3.
    Purnell, D. C., Smith, L. H., Scholz, D. A., Elveback, L. R., and Arnaud, C. D. 1971. Primary hyperparathyroidism: A prospective clinical study. Am. J. Med. 50: 670–678.PubMedCrossRefGoogle Scholar
  4. 4.
    Mallette, L. E., Bilezikian, J. P., Heath, D. A., and Aurbach, G. D. 1974. Primary hyperparathyroidism: Clinical and biochemical features. Medicine (Baltimore) 53: 127–146.Google Scholar
  5. 5.
    Watson, L. 1974. Primary hyperparathyroidism. Clin. Endocrinol. Metab. 3: 215–235.PubMedCrossRefGoogle Scholar
  6. 6.
    Myers, R. T. 1974. Followup study of surgically-treated primary hyperparathyroidism. Ann. Surg. 179: 729–733.PubMedCrossRefGoogle Scholar
  7. 7.
    George, J. M., Rabson, A. S., Ketcham, A., and Bartter, F. C. 1965. Calcareous renal disease and hyperparathyroidism. Q. J. Med. 64: 291–301.Google Scholar
  8. 8.
    Chalmers, T. M., Adams, P., Adams, J. E., Hill, L. F., Truscott, B. McN., and Smellie, W. A. B. 1972. Normocalcemic primary hyperparathyroidism, idiopathic hypercalciuria and calcium-containing renal stones. In Extrait du Symposium Rein et Calcium. Sandoz, pp. 295–306.Google Scholar
  9. 9.
    Pak, C. Y. C., East, C., Sanzenbacher, L. J., Delea, C. S., and Bartter, F. C. 1972. Gastrointestinal calcium absorption in nephrolithiasis. J. Clin. Endocrinol. Metab. 35: 261–270.PubMedCrossRefGoogle Scholar
  10. 10.
    Coe, F. L., Canterbury, J. M., Firpo, J. J., and Reiss, E. 1973. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J. Clin. Invest. 52: 134–142.PubMedCrossRefGoogle Scholar
  11. 11.
    Pak, C. Y. C., Ohata, M., Lawrence, E. C., and Snyder, W. 1974. The hypercalciurias: Causes, parathyroid functions and diagnostic criteria. J. Clin. Invest. 54: 387–400.PubMedCrossRefGoogle Scholar
  12. 12.
    Nordin, B. E. C., Peacock, M., and Wilkinson, R. 1972. Hypercalciuria and calcium stone disease. In Clinics in Endocrinology and Metabolism, Vol. 1, No. 1, I. Mclntyre, Ed. W. B. Saunders, Philadelphia, pp. 169–183.Google Scholar
  13. 13.
    Pak, C. Y. C., Kaplan, R. A., Bone, H., Townsend, J., and Waters, O. 1975. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. N. Engl. J. Med. 292: 497–500.PubMedCrossRefGoogle Scholar
  14. 14.
    Wills, M. R., Pak, C. Y. C., Hammond, W. G., and Bartter, F. C. 1969. Normocalcemic primary hyperparathyroidism. Am. J. Med. 47: 384–391.PubMedCrossRefGoogle Scholar
  15. 15.
    Frame, B., Foroozanfar, F., and Patton, R. B. 1970. Normocalcemic primary hyperparathyroidism with osteitis fibrosa. Ann. Intern. Med. 73: 253–257.PubMedGoogle Scholar
  16. 16.
    Johnson, R. D., and Conn, J. W. 1969. Hyperparathyroidism with a prolonged period of normocalcemia. J. Am. Med. Assoc. 210: 2063–2066.CrossRefGoogle Scholar
  17. 17.
    Neuman, W. F., and Neuman, M. W. 1958. The Chemical Dynamics of Bone Mineral. University of Chicago Press.Google Scholar
  18. 18.
    Robertson, W. G., Peacock, M., and Nordin, B. E. C. 1968. Activity products in stone-forming and non-stone-forming urine. Clin. Sci. 34: 579–594.Google Scholar
  19. 19.
    Finlayson, B., Roth, R., and DuBois, L. 1972. Calcium oxalate solubility studies. In Urinary Calculi: Proceedings of the International Symposium on Renal Stone Research, Madrid, 1972. L. Cifuentes Delatte, A. Rapado, and A. Hodgkinson, Eds. Karger, Basel and New York, pp. 1–7.Google Scholar
  20. 20.
    Pak, C. Y. C., Hayashi, Y., Finlayson, B., and Chu, S. 1977. Estimation of the state of saturation of brushite and calcium oxalate in urine: A comparison of three methods. J. Lab. Clin. Med. 89: 891–901.PubMedGoogle Scholar
  21. 21.
    Toribara, T. Y. 1953. Centrifuge type of ultrafiltration apparatus. Anal. Chem. 25: 1286.CrossRefGoogle Scholar
  22. 22.
    Halver, B. 1972. A rapid method for the determination of ultrafiltrable calcium in serum. Clin. Chem. 18: 1488–1492.PubMedGoogle Scholar
  23. 23.
    Moore, E. W. 1970. Ionized calcium in normal serum, ultrafiltrates, and whole blood determined by ion-exchange electrodes. J. Clin. Invest. 49: 318–334.PubMedCrossRefGoogle Scholar
  24. 24.
    Orion Research Incorporated. 1975. Model SS-20 Ionized Calcium Analyzer. Brochure.Google Scholar
  25. 25.
    Pak, C. Y. C. 1969. Physicochemical basis for the formation of renal stones of calcium phosphate origin: Calculation of the degree of saturation of urine with respect to brushite. J. Clin. Invest. 48: 1914–1922.PubMedCrossRefGoogle Scholar
  26. 26.
    Sherwood, L. M., Mayer, G. P., Rambery, C. F., Jr., Kronfeld, D. S., Aurbach, G. D., and Potts, J. T., Jr. 1968. Regulation of parathyroid hormone secretion: Proportional control by calcium, lack of effect of phosphate. Endocrinology 83: 1043–1051.PubMedCrossRefGoogle Scholar
  27. 27.
    Raisz, L. G. 1965. Bone resorption in tissue culture: Factors influencing the response to parathyroid hormone. J. Clin. Invest. 44: 103–116.PubMedCrossRefGoogle Scholar
  28. 28.
    Wills, M. R., Wortsman, J., Pak, C. Y. C., and Bartter, F. C. 1970. The role of parathyroid hormone in the gastrointestinal absorption of calcium. Clin. Sci. 39: 89–94.PubMedGoogle Scholar
  29. 29.
    Agus, Z. S., Gardner, L. B., Beck, L. H., and Goldberg, M. 1973. Effects of parathyroid hormone on renal tubular reabsorption of calcium, sodium, and phosphate. Am. J. Physiol. 224: 1143–1148.PubMedGoogle Scholar
  30. 30.
    DeLuca, H. F. 1975. The kidney as an endocrine organ involved in the function of vitamin D. Am. J. Med. 58: 39–47.CrossRefGoogle Scholar
  31. 31.
    Omdahl, J., Holick, M., Suda, T., Tanaka, Y., and DeLuca, H. F. 1971. Biological activity of 1,25-dihydroxyeholecalciferol. Biochemistry 10: 2935–2940.PubMedCrossRefGoogle Scholar
  32. 32.
    Reynolds, J. J., Holick, M. F., and DeLuca, H. F. 1973. The role of vitamin D metabolites in bone resorption. Calcif. Tissue Res. 12: 295–301.PubMedCrossRefGoogle Scholar
  33. 33.
    Puschett, J. B., Fernandez, P. C., Boyle, J. T., Gray, R. W., Omdahl, J. L., and DeLuca, H. F. 1972. The acute renal tubular effects of 1,25-dihydroxycholecalciferol. Proc. Soc. Endocrinol. Metab. 141: 379–384.Google Scholar
  34. 34.
    Garabedian, M., Holick, M. F., DeLuca, H. F., and Boyle, J. T. 1972. Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. Proc. Natl. Acad. Sci. U.S.A. 69: 1673–1676.PubMedCrossRefGoogle Scholar
  35. 35.
    Kaplan, R. A., Haussler, M. R., Deftos, L. J., Bone, H., and Pak, C. Y. C. The role of 1α,25-dihydroxycholecalciferol in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J. Clin. Invest. 59: 756–760.Google Scholar
  36. 36.
    Raisz, L. G. Au, W. Y. W., Friedman, J., and Niemann, I. 1967. Thyrocalcitonin and bone resorption. Am. J. Med. 43: 684–690.Google Scholar
  37. 37.
    Pak, C. Y. C. 1971. Parathyroid hormone and thyrocalcitonin: Their mode of action and regulation. Ann. N. Y. Acad. Sci. 179: 450–474.PubMedCrossRefGoogle Scholar
  38. 38.
    Gray, T. K., Bieberdorf, F. A., and Fordtran, J. S. 1973. Thyrocalcitonin and the jejunal absorption of calcium, water, and electrolytes in normal subjects. J. Clin. Invest. 52: 3084–3088.PubMedCrossRefGoogle Scholar
  39. 39.
    Arnaud, C. D., Tsao, H. S., and Littledike, T. 1970. Calcium homeostasis, parathyroid hormone, and calcitonin: Preliminary report. Mayo Clin. Proc. 45: 125–131.PubMedGoogle Scholar
  40. 40.
    Francis, M. D., and Webb, N. C. 1971. Hydroxyapatite formation from a hydrated calcium monohydrogen phosphate precursor. Calcif. Tissue Res. 6: 335–342.PubMedCrossRefGoogle Scholar
  41. 41.
    Pak, C. Y. C. Eanes, E. D., and Ruskin, B. 1971. Spontaneous precipitation of brushite: Evidence that brushite is the nidus of renal stones originating as calcium phosphate. Proc. Natl. Acad. Sci. U.S.A. 68: 1456–1460.PubMedCrossRefGoogle Scholar
  42. 42.
    Nordin, B. E. C., and Peacock, M. 1969. Role of kidney in regulation of plasma-calcium. Lancet 2: 1280–283.PubMedCrossRefGoogle Scholar
  43. 43.
    Keating, R. F., Jones, J. D., Elveback, L. R., and Randall, R. V. 1969. The relation of age and sex to distribution of values in healthy adults of serum calcium, inorganic phosphorus, magnesium, alkaline phosphatase, total proteins, albumin, and blood urea. J. Lab. Clin. Med. 73: 825–834.PubMedGoogle Scholar
  44. 44.
    Dauphine, R. T., Riggs, B. L., and Scholz, D. A. 1975. Back pain and vertebral crush fractures: An unemphasized mode of presentation for primary hyperparathyroidism. Ann. Intern. Med. 83: 365–367.PubMedGoogle Scholar
  45. 45.
    Lloyd, H. M. 1968. Primary hyperparathyroidism: An analysis of the role of the parathyroid tumor. Medicine (Baltimore) 47: 53–71.Google Scholar
  46. 46.
    Pak, C. Y. C., and Bartter, F. C. 1972. Treatment of osteoporosis with calcium infusions. Semin. Drug Treat. 2: 39–46.PubMedGoogle Scholar
  47. 47.
    Berlyne, G. M., Ben-Ari, J., Galinsky, D., Hirsch, M., Kushelevsky, A., and Shainkin, R. 1974. The etiology of osteoporosis: The role of parathyroid hormone. J. Am. Med. Assoc. 229: 1904–1905.CrossRefGoogle Scholar
  48. 48.
    Hossain, M., Smith, D. A., and Nordin, B. E. C. 1970. Parathyroid activity and postmenopausal osteoporosis. Lancet 1: 809–811.PubMedCrossRefGoogle Scholar
  49. 49.
    Burkhart, J. M., and Jowsey, J. 1967. Parathyroid and thyroid hormones in the development of immobilization osteoporosis. Endocrinology 81: 1053–1062.PubMedCrossRefGoogle Scholar
  50. 50.
    Jowsey, J., and Raisz, L. G. 1968. Experimental osteoporosis and parathyroid activity. Endocrinology 82: 384–396.PubMedCrossRefGoogle Scholar
  51. 51.
    Henneman, D. H., Pak, C. Y. C., Bartter, F. C., Lifschitz, M. D., and Sanzenbacher, L. 1972. The solubility and synthetic rate of bone collagen in idiopathic osteoporosis. Clin. Orthop,. Relat. Res. 88: 275–282.CrossRefGoogle Scholar
  52. 52.
    Flanagan, B., and Nichols, G., Jr. 1965. Metabolic studies of human bonem vitro. II. Changes in hyperparathyroidism. J. Clin. Invest. 44: 1795–1804.PubMedCrossRefGoogle Scholar
  53. 53.
    Atkins, D., Zanelli, J. M., Peacock, M., and Nordin, B. E. C. 1972. The effect of oestrogens on the response of bone to parathyroid hormone in vitro. J. Endocrinol 54: 107–117.PubMedCrossRefGoogle Scholar
  54. 54.
    Orimo, H., Fujita, T., and Yoshikawa, M. 1972. Increased sensitivity of bone to parathyroid hormone in ovariectomized rats. Endocrinology 90: 760–763.PubMedCrossRefGoogle Scholar
  55. 55.
    Aitken, J. M., Hart, D. M., and Lindsay, R. 1973. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br. Med. J. 3: 515–518.PubMedCrossRefGoogle Scholar
  56. 56.
    Dequeker, J. 1972. Treatment with oestrogens of primary hyperparathyroidism in postmenopausal women. Lancet 1: 747.PubMedCrossRefGoogle Scholar
  57. 57.
    Pak, C. Y. C., Stewart, A., Kaplan, R., Bone, H., Notz, C., and Browne, R. 1975. Photon absorptiometric analysis of bone density in primary hyperparathyroidism. Lancet 2: 7–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Gallagher, J. C., Riggs, B. L., Eisman, J., Arnaud, S. B., and DeLuca, H. F. 1976. Impaired production of 1,25–dihydroxy-vitamin D in postmenopausal osteoporosis. Clin. Res. 24: 580A.Google Scholar
  59. 59.
    Caputo, C. B., Meadows, D., and Raisz, L. G. Failure of estrogens and androgens to inhibit bone resorption in tissue culture. Submitted for publication.Google Scholar
  60. 60.
    Nordin, B. E. C. 1960. The effect of intravenous parathyroid extract on urinary pH, bicarbonate and electrolyte excretion. Clin. Sci. 19: 311–319.PubMedGoogle Scholar
  61. 61.
    Massry, S. G. 1977. Metabolic acidosis in hyperparathyroidism: Role of phosphate depletion and other factors. In Advances in Experimental Medicine and Biology, Vol. 81: Phosphate Metabolism. S. G. Massry and E. Ritz, Eds. Plenum, New York, pp. 301–307.Google Scholar
  62. 62.
    Pak, C. Y. C., and Holt, K. 1976. Nucleation and growth of brushite and calcium oxalate in urine of stoneformers. Metabolism 25: 665–673.PubMedCrossRefGoogle Scholar
  63. 63.
    Hodgkinson, A., and Pyrah, L. N. 1958. The urinary excretion of calcium and inorganic phosphate in 344 patients with calcium stones of renal origin. Br. J. Surg. 46: 10–18.PubMedCrossRefGoogle Scholar
  64. 64.
    Pak, C. Y. C. 1972. Nephrolithiasis (Ca-containing). Acta Endocrinol. Panam. 3: 45–52.Google Scholar
  65. 65.
    Pak, C. Y. C., and Arnold, L. H. 1975. Heterogeneous nucleation of calcium oxalate by seeds of monosodium urate. Proc. Soc. Exp. Biol. Med. 149: 930–932.PubMedGoogle Scholar
  66. 66.
    Pak, C. Y. C., Hayashi, Y., and Arnold, L. H. 1976. Heterogeneous nucleation between urate, calcium phosphate and calcium oxalate. Proc. Soc. Exp. Biol. Med. 153: 83–87.PubMedGoogle Scholar
  67. 67.
    Coe, F. L., Lawton, R. L., Goldstein, R. B., and Tembe, V. 1975. Sodium urate accelerates precipitation of calcium oxalate in vitro. Proc. Soc. Exp. Biol. Med. 149: 926–929.PubMedGoogle Scholar
  68. 68.
    Avioli, L. V., McDonald, J. E., and Singer, R. A. 1965. Excretion of pyrophosphate in disorders of bone metabolism. J. Clin. Endocrinol. Metab. 25: 912–915.PubMedCrossRefGoogle Scholar
  69. 69.
    Russell, R. G. G., and Hodgkinson, A. 1969. The urinary excretion of inorganic pyrophosphate in hyperparathyroidism, hyperthyroidism, Paget’s disease and other disorders of bone metabolism. Clin. Sci. 36:435–443.Google Scholar
  70. 70.
    Barreras, R. F. 1973. Calcium and gastric secretion. Gastroenterology 64: 1168–1184.PubMedGoogle Scholar
  71. 71.
    Trudeau, W. L., and McGuigan, J. E. 1969. Effects of calcium on serum gastrin levels in the Zollinger-Ellison syndrome. N. Engl. J. Med. 281: 862–866.PubMedCrossRefGoogle Scholar
  72. 72.
    Lindeman, R. D., Adler, S., Yiengst, M. J., and Beard, E. S. 1967. The influence of various nutrients on urinary divalent cation excretion. J. Lab. Clin. Med. 70: 236–245.PubMedGoogle Scholar
  73. 75.
    Lifschitz, M. D., Pak, C. Y. C., Henneman, D., Jowsey, J., Pilch, Y., and Bartter, F. C. 1970. Treatment of osteoporosis with calcium infusions. Trans. Assoc. Am. Physicians 83: 254–266.PubMedGoogle Scholar
  74. 74.
    Pratley, S. K., Posen, S., and Reeve, T. S. 1973. Primary hyperparathyroidism: Experiences with 60 patients. Med. J. Aust. 1: 421–426.PubMedGoogle Scholar
  75. 75.
    Irvin, G. L., III, Cohen, M. S., Moebus, R., and Mintz, D. H. 1972. Primary hyperparathyroidism. Arch. Surg. 105: 738–740.Google Scholar
  76. 76.
    Kaplan, R. A., Snyder, W. H., Stewart, A., and Pak, C. Y. C. 1976. Metabolic effects of parathyroidectomy in asymptomic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 42: 415–426.PubMedCrossRefGoogle Scholar
  77. 77.
    Boonstra, C. E., and Jackson, C. E. 1963. Hyperparathyroidism detected by routine serum calcium analysis: Prevalence in a clinic population. Ann. Intern. Med. 63: 468–474.Google Scholar
  78. 78.
    Reiss, E., and Canterbury, J. M. 1971. Genesis of hyperparathyroidism. Am. J. Med. 50: 679–685.PubMedCrossRefGoogle Scholar
  79. 79.
    Arnaud, C. D., Tsao, H. S., and Littledike, T. 1971. Radioimmunoassay of human parathyroid hormone in serum. J. Clin. Invest. 50: 21–34.PubMedCrossRefGoogle Scholar
  80. 80.
    Murad, F., and Pak, C. Y. C. 1972. Urinary excretion of adenosine 3’,5’- monophosphate and guanosine 3’,5’-monophosphate. N. Engl. J. Med. 286: 1382–1387.PubMedCrossRefGoogle Scholar
  81. 81.
    Shaw, J. W., Oldham, S. B., Rosoff, L., Bethune, J. E., and Fichman, M. P. 1977. Urinary cyclic AMP analyzed as a function of the serum calcium and parathyroid hormone in the differential diagnosis of hypercalcemia. J. Clin. Invest. 59: 14–21.PubMedCrossRefGoogle Scholar
  82. 82.
    Neelon, F. A., Drezner, M., Birch, B. M., and Lebovitz, H. E. 1973. 1 Urinary cyclic adenosine monophosphate as an aid in the diagnosis of hyper- I parathyroidism. Lancet 1: 631–634.Google Scholar
  83. 83.
    Brickman, A. S., Massry, S. G., and Coburn, J. W. 1972. Changes in serum 1 and urinary calcium during treatment with hydrochlorothiazide studies on mechanisms. J. Clin. Invest. 51:945–954. ?Google Scholar
  84. 84.
    Pariitt, A. M. 1969. Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. N. Engl. J. Med. 281: 55–59.CrossRefGoogle Scholar
  85. 85.
    Pronove, P., Bell, N. H., and Bartter, F. C. 1961. Production of hypercalciuria by phosphorus deprivation on a low calcium intake: A new clinical test for hyperparathyroidism. Metabolism 10: 364–370.PubMedGoogle Scholar
  86. 86.
    Chase, L. R., and Aurbach, G. D. 1968. Renal adenyl cyclase: Anatomically separate sites for parathyroid hormone and vasopressin. Science 159: 545–547.PubMedCrossRefGoogle Scholar
  87. 87.
    Tucci, J. R., Lin, T., and Kopp, L. 1973. Urinary cyclic 3’,5’-adenosine monophosphate levels in diabetes mellitus before and after treatment. J. Clin. Endocrinol. Metab. 37: 832–835.PubMedCrossRefGoogle Scholar
  88. 88.
    Ball, J. H., Kaminsky, N. I., Hardman, J. G., Broadus, A. E., Sutherland, E. W., and Liddle, G. W. 1972. Effects of catecholamines and adrenergicblocking agents on plasma and urinary cyclic nucleotides in man. J. Clin. Invest. 51: 2124–2129.PubMedCrossRefGoogle Scholar
  89. 89.
    Chase, L. R., and Aurbach, G. D. 1968. Renal adenyl cyclase: Anatomically separate sites for parathyroid hormone and vasopressin. Science 159: 545–547.PubMedCrossRefGoogle Scholar
  90. 90.
    Lin, T., Kopp, L. E., and Tucci, J. R. 1973. Urinary excretion of cycles’, 5’-adenosine monophosphate in hyperthyroidism. J. Clin. Endocrinol. Metab. 36: 1033–1036.PubMedCrossRefGoogle Scholar
  91. 91.
    Schmidt-Gayk, H., Seitz, H., Stengel, R., and Ritz, E. 1975. Secondary hyperparathyroidism of gastrointestinal and renal origin: Influence of renal function on urinary cyclic AMP. In 12th International Congress of Internal Medicine, Tel Aviv, 1974. Karger, Basel, pp. 130–134.Google Scholar
  92. 92.
    Babka, J. C., Bower, R. H., and Sode, J. 1976. Nephrogenous cyclic AMP levels in primary hyperparathyroidism. Arch. Intern. Med. 136: 1140–1144.PubMedCrossRefGoogle Scholar
  93. 93.
    Palmer, F. J., Nelson, J. C., and Bacchus, H. 1974. The chloridephosphate ratio in hypercalcemia. Ann. Intern. Med. 80: 200–204.PubMedGoogle Scholar
  94. 94.
    Reeves, C. D., Palmer, F., Bacchus, H., and Longerbeam, J. K. 1975. Dif ferential diagnosis of hypercalcemia by the chloride/phosphate ratio. Am. J. Surg. 130: 166–171.PubMedCrossRefGoogle Scholar
  95. 95.
    Drago, J. R., Rohner T. J., Sanford, E. J., and Santen, R. E. 1976. Diagnosis of hyperparathyroidism. Urology 7: 4–6.PubMedCrossRefGoogle Scholar
  96. 96.
    Pak, C. Y. C., and Townsend, J. 1976. Chloride:phosphorus in primary hyperparathyroidism. Ann. Intern. Med. 85: 830.PubMedGoogle Scholar
  97. 97.
    Williamson, E., and VanPeenen, 1974. Patient benefit in discovering occult hyperparathyroidism. Arch. Intern. Med. 133: 430–431.PubMedCrossRefGoogle Scholar
  98. 98.
    Hellstrom, J., and Ivemark, B. I. 1962. Primary hyperparathyroidism: Clinical and structural findings in 138 cases. Acta Chir. Scand. (Suppl.) 294: 1–113.Google Scholar
  99. 99.
    Barilla, D. E., and Pak, C. Y. C. In preparation.Google Scholar
  100. 100.
    Dent, C. E. 1962. Some problems of hyperparathyroidism. Br. Med. J. 2: 1419–1425.PubMedCrossRefGoogle Scholar
  101. 101.
    Pyrah, L. N., Hodgkinson, A., and Anderson, C. K. 1966. Primary hyperparathyroidism: A critical review. Br. J. Surg. 53: 245–316.PubMedCrossRefGoogle Scholar
  102. 102.
    Roth, S. I. 1962. Pathology of the parathyroid in hyperparathyroidism. Arch. Pathol. 73: 495–510.PubMedGoogle Scholar
  103. 103.
    Pak, C. Y. C., East, D., Sanzenbacher, L., Ruskin, B. S., and Cox, J. 1972. A simple and reliable test for the diagnosis of hyperparathyroidism. Arch. Intern. Med. 129: 48–55.PubMedCrossRefGoogle Scholar
  104. 104.
    Sanzenbacher, L. J., East, D. A., Pak, C. Y. C., and Bartter, F. C. 1970. Pre- and post-operative evaluation of patients with normocalcemic primary hyperparathyroidism. Surg. Forum, pp. 96–98.Google Scholar
  105. 105.
    Albright, F. 1941. Case records of the Massachusetts General Hospital (Case 27461). N. Engl. J. Med. 225: 789–791.CrossRefGoogle Scholar
  106. 106.
    Plimpton, C. H., and Gellhorn, A. 1956. Hypercalcemia in malignant disease without evidence of bone destruction. Am. J. Med. 21: 750–759.PubMedCrossRefGoogle Scholar
  107. 107.
    Omenn, G. S., Roth, S. I., and Baker, W. H. 1969. Hyperparathyroidism associated with malignant tumors of nonparathyroid origin. Cancer 24: 1004–1012.PubMedCrossRefGoogle Scholar
  108. 108.
    Lafferty, F. W. 1966. Pseudohyperparathyroidism. Medicine (Baltimore) 45: 247–260.CrossRefGoogle Scholar
  109. 109.
    Snedecor, P. A., and Baker, H. W. 1964. Pseudohyperparathyroidism due to malignant tumors. Cancer 17: 1492–1496.PubMedCrossRefGoogle Scholar
  110. 110.
    Riggs, B. L., Arnaud, C. D., Reynolds, J. C., and Smith, L. H. 1971. Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to nonparathyroid cancer. J. Clin. Invest. 50: 2079–2083.PubMedCrossRefGoogle Scholar
  111. 111.
    Palmieri, G. M. A., Nordquist, R. E., and Omenn, G. S. 1974. Immunochemical localization of parathyroid hormone in cancer tissue from patients with ectopic hyperparathyroidism. J. Clin. Invest. 53: 1726–1735.PubMedCrossRefGoogle Scholar
  112. 112.
    Goldhaber, P. 1960. Enhancement of bone resorption in tissue culture by mouse fibrosarcoma. Proc. Am. Assoc. Cancer Res. 3: 113.Google Scholar
  113. 113.
    Tashjian, A. H., Jr., Voelkel, E. F., Levine, L., and Goldhaber, P. 1972. Evidence that the bone resorptionstimulating factor produced by mouse fibrosarcoma cells is prostaglandin E2: A new model for the hypercalcemia of cancer J. Exp. Med. 136: 1329–1343.PubMedCrossRefGoogle Scholar
  114. 114.
    Klein, D. C., and Raisz, L. G. 1970. Prostaglandins: Stimulation of bone resorption in tissue culture. Endocrinology 86: 1436–1440.PubMedCrossRefGoogle Scholar
  115. 115.
    Powell, D., Singer, F. R., Murray, T. M., Minkin, C., and Potts, J. T., Jr. 1973. Nonparathyroid humoral hypercalcemia in patients with neoplastic diseases. N. Engl J. Med. 289: 176–181.PubMedCrossRefGoogle Scholar
  116. 116.
    Robertson, R. P., Baylink, D. J., Marini, J. J., and Adkison, H. W. 1975. Elevated prostaglandins and suppressed parathyroid hormone associated with hypercalcemia and renal cell carcinoma. J. Clin. Endocrinol. Metab. 41: 164–167.PubMedCrossRefGoogle Scholar
  117. 117.
    Seyberth, H. W., Segre, G. V., Morgan, J. L., Sweetman, B. J., Potts, J. T., Jr., and Oates, J. A. 1975. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N. Engl. J. Med. 293: 1278–1283.PubMedCrossRefGoogle Scholar
  118. 118.
    Horton, J. E., Raisz, L. G., Simmons, H. A., Oppenheim, J. J., and Mergenhagen, S. E. 1972. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science 177: 793–795.PubMedCrossRefGoogle Scholar
  119. 119.
    Mundy, G. R., Luben, R. A., Raisz, L. G., Oppenheim, J. J., and Buell, D. N. 1974. Boneresorbing activity in supernatants from lymphoid cell lines. N. Engl. J. Med. 290: 867–871.PubMedCrossRefGoogle Scholar
  120. 120.
    Luben, R. A., Mundy, G. R., Trummel, C. L., and Raisz, L. G. 1974. Partial purification of osteoclast-activating factor from phytohemagglutininstimulated leukocytes. J. Clin. Invest. 53: 1473–1480.PubMedCrossRefGoogle Scholar
  121. 121.
    Raisz, L. G. 1973. Prostaglandins and the hypercalcemia of cancer. N. Engl. J. Med. 289: 214–215.PubMedCrossRefGoogle Scholar
  122. 122.
    Gordan, G. S., Cantino, T. J., Erhardt, L., Hansen, J., and Lubich, W. 1966. Osteolytic sterol in human breast cancer. Science 151: 1226–1228.CrossRefGoogle Scholar
  123. 123.
    Davis, H. L., Wiseley, A. N., Ramirez, G., and Ansfield, F. J. 1973. Hypercalcemia complicating breast cancer. Oncology 28: 126–137.PubMedCrossRefGoogle Scholar
  124. 124.
    Bell, N. H., Gill, J. R., Jr., and Bartter, F. C. 1964. On the abnormal calcium absorption in sarcoidosis. Am. J. Med. 36: 500–513.PubMedCrossRefGoogle Scholar
  125. 125.
    Bell, N. H., and Bartter, F. C. 1964. Transient reversal of hyperabsorption of calcium and of abnormal sensitivity to vitamin D in a patient with sarcoidosis during episode of nephritis. Ann. Intern. Med. 61: 702–710.PubMedGoogle Scholar
  126. 126.
    Bell, N. H., Sinha, T. K., and DeLuca, H. F. 1976. Mechanism for abnormal calcium metabolism in sarcoidosis. Clin. Res. 24: 484.Google Scholar
  127. 127.
    Burnett, C. H., Commons, R. R., Albright, F., and Howard, J. E. 1949. Hypercalcemia without hypercalciuria or hypophosphatemia, calcinosis and renal insufficiency. N. Engl. J. Med. 240: 787–794.PubMedCrossRefGoogle Scholar
  128. 128.
    Lotz, M., Zisman, E., and Bartter, F. C. 1968. Evidence for a phosphorus depletion syndrome in man. N. Engl. J. Med. 278: 409–415.PubMedCrossRefGoogle Scholar
  129. 129.
    Huges, M. R., Brumbaugh, P. F., Haussler, M. R., Wergedal, J. E., and Baylink, D. J. 1975. Regulation of serum lα,25-dihydroxyvitamin D3 by calcium and phosphate in the rat. Science 190: 578–580.CrossRefGoogle Scholar
  130. 130.
    Bruin, W. J., Baylink, D. J., and Wergedal, J. E. 1975. Acute inhibition of mineralization and stimulation of bone resorption mediated by hypophosphatemia. Endocrinology 96: 394–399.PubMedCrossRefGoogle Scholar
  131. 131.
    Middler, S., Pak, C. Y. C., Murad, F., and Bartter, F. C. 1973. Thiazide diuretics and calcium metabolism. Metabolism 22: 139–146.PubMedCrossRefGoogle Scholar
  132. 132.
    Garcia, D. A., and Yendt, E. R. 1970. The effects of probenecid and thiazides and their combination on the urinary excretion of electrolytes and on acid-base equilibrium. Can. Med. Assoc. J. 103: 473–483.PubMedGoogle Scholar
  133. 133.
    Pickelman, J., Paloyan, E., Forland, M., and Strauss, F. H. 1968. Thiazide induced parathyroid stimulation. Clin. Res. 16: 468.Google Scholar

Copyright information

© Plenum Publishing Corporation 1978

Authors and Affiliations

  • Charles Y. C. Pak
    • 1
  1. 1.The University of Texas Health Science CenterDallasUSA

Personalised recommendations